Additional file 5: of Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
posted on 2019-01-07, 05:00authored byAxel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe OâSullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad
Table S5. Summary of treatment-related adverse events by symptom status. (DOCX 31 kb)